174 related articles for article (PubMed ID: 26202607)
21. A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction.
Cheng Z; Luo Y; Zhang Y; Wang Y; Chen Y; Xu Y; Peng H; Zhang G
Ann Hematol; 2020 Jul; 99(7):1561-1564. PubMed ID: 32451710
[TBL] [Abstract][Full Text] [Related]
22. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
23. Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
Cai P; Liu S; Duan L; Huo L; Wu D; Chen S; Yang R; Yang X
Acta Haematol; 2023; 146(5):397-400. PubMed ID: 37562364
[TBL] [Abstract][Full Text] [Related]
24. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Miyazawa K; Kakazu N; Ohyashiki K
Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
[TBL] [Abstract][Full Text] [Related]
25. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
[No Abstract] [Full Text] [Related]
26. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Fernández-Rodríguez C; Besses C
Br J Haematol; 2016 Feb; 172(4):639-42. PubMed ID: 26115187
[No Abstract] [Full Text] [Related]
28. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
[TBL] [Abstract][Full Text] [Related]
30. Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.
Chaudhary LN; Bailey NG; Vos JA; Stotler CJ
W V Med J; 2013; 109(2):6-9. PubMed ID: 23600098
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
[No Abstract] [Full Text] [Related]
32. PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
Kaplan HG; Jin R; Bifulco CB; Scanlan JM; Corwin DR
Oncologist; 2022 Aug; 27(8):e661-e670. PubMed ID: 35472244
[TBL] [Abstract][Full Text] [Related]
33. Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
Prochorec-Sobieszek M; Nasiłowska-Adamska B; Borg K; Kopeć I; Kos-Zakrzewska K; Juszczyński P; Warzocha K
Leuk Lymphoma; 2012 Sep; 53(9):1824-7. PubMed ID: 22288769
[No Abstract] [Full Text] [Related]
34. Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion.
Van Thillo Q; Dewaele B; De Bie J; Michaux L; Devos T; Vandenberghe P
Br J Haematol; 2023 Jul; 202(1):e7-e10. PubMed ID: 37129059
[No Abstract] [Full Text] [Related]
35. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
[No Abstract] [Full Text] [Related]
36. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
[No Abstract] [Full Text] [Related]
37. Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
Yoshida M; Tamagawa N; Nakao T; Kanashima H; Ueda H; Murakami A; Yorifuji T; Yamane T
Leuk Lymphoma; 2015 Mar; 56(3):768-9. PubMed ID: 24975316
[No Abstract] [Full Text] [Related]
38. [Ruxolitinib prescription in myelofibrosis].
Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
[TBL] [Abstract][Full Text] [Related]
39. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
Roufosse F; Goldman M; Cogan E
Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
[TBL] [Abstract][Full Text] [Related]
40. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of
Zhang L; Zhu X; Qu W; Lu Y; Feng Z; Zhao L
Haematologica; 2023 Dec; 108(12):3506-3510. PubMed ID: 37102606
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
